Key facts
- This page summarizes Eric Devroe's Form 3 filing for Acrivon Therapeutics, Inc. (ACRV).
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 09 Nov 2022, 19:30.
Eric Devroe - 09 Nov 2022 Form 3 Insider Report for Acrivon Therapeutics, Inc. (ACRV)
- Reporting relationship
- Chief Operating Officer
- Issuer ticker
- ACRV
- Reported as of
- 09 Nov 2022
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 09 Nov 2022, 19:30:46 UTC
- Next SEC filing
- 16 Nov 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Rasmus Holm-Jorgensen, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Eric Devroe filed Form 3 for Acrivon Therapeutics, Inc. (ACRV) on 09 Nov 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ACRV
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 20,275
- Date
- 09 Nov 2022
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ACRV
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 09 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 105,840
- Exercise price
- $1.04
- Footnotes
- F1
ACRV
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 09 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 94,586
- Exercise price
- $3.88
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The original grant was for 126,115 shares, which was partially exercised for 20,275 shares of common stock. Twenty-five percent (25%) of the shares subject to the option vested on October 5, 2021, and the remaining shares subject to the option vested or shall vest in 12 equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.
Footnote F2
The shares subject to the option vested or shall vest quarterly on the last day of each quarter for 16 quarters following January 1, 2022, in each case subject to the Reporting Person's continuous service through each such vesting date.
SEC remarks
Exhibit List - Exhibit 24 - Power of Attorney